A microRNA code for prostate cancer metastasis

Ruggero De Maria Marchiano, D. Bonci, V. Coppola, M. Patrizii, A. Addario, A. Cannistraci, F. Francescangeli, R. Pecci, G. Muto, D. Collura, R. Bedini, A. Zeuner, M. Valtieri, S. Sentinelli, M. S. Benassi, M. Gallucci, P. Carlini, S. Piccolo

Research output: Contribution to journalArticle

88 Citations (Scopus)


Lung cancer is the most common cause of cancer-related mortality worldwide, urging the discovery of novel molecular targets and therapeutic strategies. Stem cells have been recently isolated from non-small cell lung cancer (NSCLC), thus allowing the investigation of molecular pathways specifically active in the tumorigenic population. We have found that Bcl-XL is constantly expressed by lung cancer stem cells (LCSCs) and has a prominent role in regulating LCSC survival. Whereas chemotherapeutic agents were scarcely effective against LCSC, the small molecule Bcl-2/Bcl-XL inhibitor ABT-737, but not the selective Bcl-2 inhibitor ABT-199, induced LCSC death at nanomolar concentrations. Differently from gemcitabine, which preferentially eliminated proliferating LCSC, ABT-737 had an increased cytotoxic activity in vitro towards quiescent/slow-proliferating LCSC, which expressed high levels of Bcl-XL. In vivo, ABT-737 as a single agent was able to inhibit the growth of LCSC-derived xenografts and to reduce cancer stem cell content in treated tumors. Altogether, these results indicate that quiescent/slow-proliferating LCSC strongly depend on Bcl-XL for their survival and indicate Bcl-XL inhibition as a potential therapeutic avenue in NSCLC.
Original languageEnglish
Pages (from-to)1180-1192
Number of pages13
Publication statusPublished - 2016


  • cancer

Fingerprint Dive into the research topics of 'A microRNA code for prostate cancer metastasis'. Together they form a unique fingerprint.

Cite this